DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Clinical trials for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS trials appear
Sign up with your email to follow new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for scleroderma: arthritis drug tofacitinib tested against skin thickening
Disease control CompletedThis study tested whether tofacitinib (a JAK inhibitor drug) works better than methotrexate (a standard treatment) at reducing skin thickening in people with a severe form of scleroderma called diffuse cutaneous systemic sclerosis. Thirty-four adults with early-stage disease took…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE4 • Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug shows promise for rare Skin-Hardening disease
Disease control CompletedThis study tested a new drug called MT-7117 (dersimelagon) in 76 people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes skin thickening and can affect internal organs. Participants received either the drug or a placebo for 52 weeks. The main goal …
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Cancer drug repurposed to fight rare skin disease in small safety trial
Symptom relief CompletedThis early-phase study tested whether a drug used for lymphoma, brentuximab vedotin, is safe for people with a severe form of scleroderma (diffuse cutaneous systemic sclerosis). The drug targets overactive immune cells that may drive the disease. Only 17 people took part, and the…
Matched conditions: DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC